Navellier & Associates Inc Prothena Corp Public LTD CO Transaction History

Navellier & Associates Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$30.27 - $49.22 $228,629 - $371,758	-7,553 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $15,707 - $27,325	373 Added 5.19%	7,553 $373,000
Q3 2021 Oct 28, 2021	BUY	$48.2 - $78.89 $346,076 - $566,430	7,180 New	7,180 $511,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $685M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.